Education
About Us
Working with TipRanks
Follow Us
Arcellx, Inc. (ACLX)
:ACLX
ACLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.86 - $107.37
Previous CloseN/A
Volume227.93K
Average Volume (3M)531.04K
Market Cap
$4.68B
Enterprise Value$3.30B
Total Cash (Recent Filing)$543.26M
Total Debt (Recent Filing)$53.19M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 17, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding55,458,910
10 Day Avg. Volume512,303
30 Day Avg. Volume531,041
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue42.98
Enterprise Value/Gross Profit43.69
Enterprise Value/Ebitda-20.36
Forecast
1Y Price Target
$116.27Price Target Upside37.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Commercial StrategyPlans are in place to launch anito-cel in 160+ treatment centers, indicating a strong commercial strategy.
Product SafetyAnito-cel is clearly differentiated on toxicity, with zero observations of parkinsonism, cranial nerve palsy, and enterocolitis events.
Regulatory ApprovalArcellx's BLA filing for anito-cel should include more than 12 months median follow-up time for responders, supporting a high probability of approval.
Bears Say
Market CompetitionThe overall median follow-up time for anito-cel responders should be longer than Bristol's ABECMA and similar to Legend / JNJ's CARVYKTI, positioning it favorably for FDA approval, yet indicating tough competition.
Market VolatilitySignificant stock-moving potential is anticipated for ACLX, with expectations of substantial impacts following the ASH presentation, indicating potential volatility.
Arcellx Inc News
ACLX FAQ
What was Arcellx, Inc.’s price range in the past 12 months?
Arcellx, Inc. lowest stock price was $47.86 and its highest was $107.37 in the past 12 months.
What is Arcellx, Inc.’s market cap?
Arcellx, Inc.’s market cap is $4.68B.
When is Arcellx, Inc.’s upcoming earnings report date?
Arcellx, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 40 days.
How were Arcellx, Inc.’s earnings last quarter?
Arcellx, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.005 by $0.065.
Is Arcellx, Inc. overvalued?
According to Wall Street analysts Arcellx, Inc.’s price is currently Undervalued.
Does Arcellx, Inc. pay dividends?
Arcellx, Inc. does not currently pay dividends.
What is Arcellx, Inc.’s EPS estimate?
Arcellx, Inc.’s EPS estimate is -0.99.
How many shares outstanding does Arcellx, Inc. have?
Arcellx, Inc. has 55,458,910 shares outstanding.
What happened to Arcellx, Inc.’s price movement after its last earnings report?
Arcellx, Inc. reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.005. Following the earnings report the stock price went down -0.914%.
Which hedge fund is a major shareholder of Arcellx, Inc.?
Currently, no hedge funds are holding shares in ACLX
Arcellx Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.27 (37.79% Upside)
$116.27 (37.79% Upside)
Blogger Sentiment
Neutral
ACLX Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 216.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.01%
12-Months-Change
Fundamentals
Return on Equity
-42.75%
Trailing 12-Months
Asset Growth
-15.69%
Trailing 12-Months
Company Description
Arcellx, Inc.
Arcellx Inc (ACLX) is a biotechnology company focused on developing innovative therapies for patients with cancer and other severe diseases. The company specializes in the development of its proprietary cell therapy platform, which leverages the unique properties of genetically engineered T cells to target and eliminate cancer cells. Arcellx is primarily engaged in the research, development, and commercialization of its lead product candidates, which are designed to address significant unmet medical needs in hematologic malignancies and other related conditions.
ACLX Stock 12 Month Forecast
Average Price Target
$116.27
▲(37.79% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
4.94% Insiders
28.99% Mutual Funds
2.04% Other Institutional Investors
49.45% Public Companies and Individual Investors